Brainstorm Cell Therapeutics Inc. News Releases http://ir.brainstorm-cell.com/ Brainstorm Cell Therapeutics Inc. News Releases en BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-ceo-present-world-advanced-therapy-and-regenerative-0 NEW YORK and LONDON , May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( Nasdaq: BCLI ), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits , president and CEO, will provide an update on the Company’s two Mon, 13 May 2019 01:00:00 -0400 Brainstorm Cell Therapeutics Inc. News Releases 9491 BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate Update http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-announces-financial-results-first-quarter-2019-and Highlights Scientific Advances and Continued Progress in NurOwn ® ALS Phase 3 Trial  and Progressive MS Phase 2 Trial; Expansion of the proprietary cellular technology platform NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. Fri, 10 May 2019 17:00:00 -0400 Brainstorm Cell Therapeutics Inc. News Releases 9481 BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorms-cellular-technology-platform-expanded-include NEW YORK , April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc. , ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced that it has expanded its proprietary cellular technology platform to include NurOwn®-derived Tue, 30 Apr 2019 04:00:00 -0400 Brainstorm Cell Therapeutics Inc. News Releases 9476 Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting http://ir.brainstorm-cell.com/news-releases/news-release-details/two-brainstorm-scientific-abstracts-accepted-presentation-71st Abstracts to highlight NurOwn® mechanism of action and correlation of Phase 2 clinical outcomes with ALS disease biomarkers NEW YORK , March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly Thu, 28 Mar 2019 04:30:00 -0400 Brainstorm Cell Therapeutics Inc. News Releases 9461 BrainStorm Announces Grant of an additional New European Patent for NurOwn® http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-announces-grant-additional-new-european-patent NEW YORK , March 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the European Patent Office ("EPO") has granted a European-wide patent titled 'Mesenchymal Stem Tue, 26 Mar 2019 06:30:00 -0400 Brainstorm Cell Therapeutics Inc. News Releases 9456 BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-announces-first-patient-enrolled-phase-2-clinical Enrollment Announced During MS Awareness Week NEW YORK and CLEVELAND , March 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Thu, 14 Mar 2019 01:00:00 -0400 Brainstorm Cell Therapeutics Inc. News Releases 9451 BrainStorm to Host Business Update Conference Call http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-host-business-update-conference-call Tuesday, March 12th at 8.30am EDT NEW YORK , March 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, will hold a conference call on Tuesday, March 12 Thu, 07 Mar 2019 04:00:00 -0500 Brainstorm Cell Therapeutics Inc. News Releases 9431 BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-announces-first-contracted-us-clinical-site-phase-2 Phase 2 Open-Label Trial of Autologous MSC-NTF Cell Therapy (NurOwn®) in Progressive MS Patients will Begin Enrollment in Early 2019 NEW YORK and CLEVELAND , Feb. 22, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc.  ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular Fri, 22 Feb 2019 07:30:00 -0500 Brainstorm Cell Therapeutics Inc. News Releases 9411 BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-present-2019-sachs-associates-european-life-sciences ZURICH, Switzerland and NEW YORK , Feb. 21, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits , CEO will present at the Thu, 21 Feb 2019 06:00:00 -0500 Brainstorm Cell Therapeutics Inc. News Releases 9406 BrainStorm Issues a Statement to Patients and Shareholders http://ir.brainstorm-cell.com/news-releases/news-release-details/brainstorm-issues-statement-patients-and-shareholders NEW YORK , Feb. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, in response to numerous requests, issues today the following statement: We will begin by Tue, 19 Feb 2019 08:06:00 -0500 Brainstorm Cell Therapeutics Inc. News Releases 9386